How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

478 results for

Lyme Disease Vaccine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review. (Full text)

The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review. While Lyme disease (LD) is mostly treatable, misdiagnosed or untreated LD can result in debilitating sequelae and excessive healthcare usage. The objective of this review was to characterize the body of literature on the economic burden of Lyme disease (LD) and the cost-effectiveness of LD interventions, such as antibiotic treatment and vaccination.We followed Joanna Briggs Institute (...) ), 142,562 USD in Sweden (0.014 USD per capita, 9.96M), 40.88M USD in Germany (0.51 USD per capita, 80.59M), 23.12M USD in the Netherlands (1.36 USD per capita, 17.08M), and up to 786M USD in the US (2.41 USD per capita, 326.63M).Lyme disease imposes an economic burden that could be considered significant in the US and other developed countries to justify further research efforts in disease control and management. Societal costs for Lyme disease can be equally impactful as healthcare costs

2019 PLoS ONE PubMed

2. Lyme disease

be neurological, cardiac, or musculoskeletal. Mainstay of treatment is antibiotic therapy. There is currently no vaccine; prevention is centred around reducing exposure to ticks. Definition Lyme disease is a zoonotic infection caused by a spirochete of genus Borrelia , which is transmitted to humans by ticks. Zoonotic diseases are transmitted between vertebrate animals and humans. Animals serve as the primary reservoir of Borrelia . Ticks become infected by feeding on an infected animal. Most common initial (...) Lyme disease Lyme disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Lyme disease Last reviewed: February 2019 Last updated: November 2018 Summary Erythema migrans develops at the site of tick bite usually within 1 to 2 weeks and is a pathognomic feature of Lyme disease. Constitutional symptoms such as fever, headache, myalgias, fatigue, and arthralgias may occur. Complications of Lyme disease may

2018 BMJ Best Practice

3. Lyme disease

be neurological, cardiac, or musculoskeletal. Mainstay of treatment is antibiotic therapy. There is currently no vaccine; prevention is centred around reducing exposure to ticks. Definition Lyme disease is a zoonotic infection caused by a spirochete of genus Borrelia , which is transmitted to humans by ticks. Zoonotic diseases are transmitted between vertebrate animals and humans. Animals serve as the primary reservoir of Borrelia . Ticks become infected by feeding on an infected animal. Most common initial (...) Lyme disease Lyme disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Lyme disease Last reviewed: February 2019 Last updated: November 2018 Summary Erythema migrans develops at the site of tick bite usually within 1 to 2 weeks and is a pathognomic feature of Lyme disease. Constitutional symptoms such as fever, headache, myalgias, fatigue, and arthralgias may occur. Complications of Lyme disease may

2018 BMJ Best Practice

4. A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development. (Full text)

A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development. Lyme borreliosis (LB) is the most prevalent arthropod-borne infectious disease in North America. Currently, no vaccine is available to prevent LB in humans, although monovalent and multivalent vaccines have been developed in the past.The aim of the current study is to conduct a systematic review and meta-analysis to evaluate and compare (...) the findings from these two classes of vaccines for their reactogenicity, immunogenicity and efficacy, in the hope this may assist in the development of future vaccines.A search strategy was developed for online databases (PubMed, Ovid MEDLINE, and Embase). Search terms used were "vaccine/vaccination", "Lyme disease/Borreliosis", "clinical trial(s)" and "efficacy". Only seven clinical trials were included to compare the results of the monovalent vaccines to those of the multivalent one. Meta-analyses were

2017 Canadian journal of public health = Revue canadienne de sante publique PubMed

5. Prevalence, diagnosis, treatment and prevention of Lyme disease: an evidence map and four systematic reviews

(such as wearing insect repellent or protective clothing) may prevent Lyme disease. Education strategies may improve adults’ knowledge about Lyme disease but for children the evidence is less clear. Even when knowledge is improved this does not seem to result in fewer tick bites or cases of Lyme disease. Evidence on other approaches such as vaccination and control of tick populations was limited. The evidence for all approaches was generally of poor quality and none of the studies were from the UK. What (...) Prevalence, diagnosis, treatment and prevention of Lyme disease: an evidence map and four systematic reviews Lyme disease 18 March 2019 Links Download reports (pdf) Prevalence, diagnosis, treatment and prevention of Lyme disease: an evidence map and four systematic reviews What do we want to know? Lyme disease is the result of a bacterial infection which is common in ticks; people can develop Lyme disease after being bitten by an infected tick. Evidence indicates that rates of Lyme disease may

2017 EPPI Centre

6. Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine (Full text)

Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, the most common tick-borne disease in the US and Europe. No potent human vaccine is currently available. The innate immune complement system is vital to host defense against pathogens, as complement activation on the surface of spirochetes results in bacterial (...) immunogenicity. We observed greater bactericidal antibody titers in mice vaccinated with modified VLP-CspZ: A serum dilution of 1:395 (modified VLP-CspZ) vs 1:143 (VLP-CspZ) yielded 50% borreliacidal activity. Immunizing mice with modified VLP-CspZ cleared spirochete infection, as did passive transfer of elicited antibodies. This work developed a novel Lyme disease vaccine candidate by conjugating CspZ to VLP and eliminating FH-binding ability. Such a strategy of conjugating an antigen to a VLP

2018 Frontiers in immunology PubMed

7. Design of a Lyme Disease Vaccine as an Active Learning Approach in a Novel Interdisciplinary Graduate-Level Course (Full text)

Design of a Lyme Disease Vaccine as an Active Learning Approach in a Novel Interdisciplinary Graduate-Level Course A biomedical sciences graduate program needed an introductory class that would develop skills for students interested in a wide variety of disciplines, such as microbiology or cancer biology, and a diverse array of biomedical careers. Faculty created a year-long student-centered course, Scientific Discovery, to serve this need. The course was divided into four modules (...) , such as the ability to conduct scholarly inquiry. In 2015, the theme of the infectious disease module was to create an effective human vaccine to prevent Lyme disease. The module required students to learn fundamental concepts of microbiology and immunology and then apply that knowledge to design their own Lyme disease vaccine. The class culminated with students communicating their creative designs in the form of a "white paper" and a pitch to "potential investors." By the end of the module, students had

2017 Journal of Microbiology & Biology Education PubMed

8. Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release (Full text)

Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release The incidence of Lyme disease has continued to rise despite attempts to control its spread. Vaccination of zoonotic reservoirs of human pathogens has been successfully used to decrease the incidence of rabies in raccoons and foxes. We have previously reported on the efficacy of a vaccinia virus vectored vaccine to reduce carriage (...) of Borrelia burgdorferi in reservoir mice and ticks. One potential drawback to vaccinia virus vectored vaccines is the risk of accidental infection of humans. To reduce this risk, we developed a process to encapsulate vaccinia virus with a pH-sensitive polymer that inactivates the virus until it is ingested and dissolved by stomach acids. We demonstrate that the vaccine is inactive both in vitro and in vivo until it is released from the polymer. Once released from the polymer by contact with an acidic pH

2016 Vaccine PubMed

9. Lyme Disease Vaccine

Lyme Disease Vaccine Lyme Disease Vaccine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Lyme Disease Vaccine Lyme Disease Vaccine (...) Aka: Lyme Disease Vaccine , LYMErix From Related Chapters II. Background no longer available in U.S. III. Indication: Prevention of Lyme Disease in high risk areas Ages 15 to 70 years old Live, work or recreate in high risk areas Frequent or prolonged exposure IV. Mechanism Recombinant outer surface protein Antibodies responding to form Destroy s in tick gut prior to transmission V. Efficacy Studied in 20 month, double blind trial (n=11,000) After 2 doses: 49% effective After 3 doses: 76

2018 FP Notebook

10. Intentions to receive a potentially available Lyme disease vaccine in an urban sample (Full text)

Intentions to receive a potentially available Lyme disease vaccine in an urban sample The only human Lyme disease vaccine of LYMErix was voluntarily removed from the market in the United States in 2002 for a number of reasons. A new human Lyme disease vaccine is currently being developed. We would like any future approved human Lyme disease vaccine to be of interest and marketable to consumers.We surveyed 714 participants to determine variables associated with intentions to receive a Lyme (...) disease vaccine. Predictor variables included demographics, protection motivational theory, Lyme disease knowledge, Lyme disease preventive behaviors, beliefs and perceived health.We found in multivariate linear regression analyses that Asian/Asian American race/ethnicity (p < 0.001), South Asian race/ethnicity (p = 0.01) and coping appraisal variables of response efficacy (p < 0.001) and self-efficacy (p < 0.001) were each significantly associated with increased intentions. The belief that vaccines

2016 Therapeutic advances in vaccines PubMed

11. Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

2 study conducted in two study phases: a run-in phase and a main study phase. The study will investigate 3 doses of a multivalent OspA (Outer Surface Protein A)based Lyme vaccine (VLA15) in healthy adults aged 18 to 65 years of age. Study participants will receive 3 immunizations of the vaccine at a monthly interval. The study will assess the immune response as well as the safety profile of the vaccine. Condition or disease Intervention/treatment Phase Lyme Borreliosis Biological: VLA15 (...) prior to Visit 0; Subject received previous vaccination against Lyme borreliosis (LB).; Subject had a tick bite within 4 weeks prior to Visit 1; Subject has a medical history of or currently has a clinically relevant disease (cardiovascular, respiratory, neurologic, psychiatric conditions) which poses a risk for participation in the study, based on investigators judgement, such as individuals with poorly controlled or unstable disease, ongoing suspected or active inflammation, or poor compliance

2018 Clinical Trials

12. Deaths and complications due to treating the fake disease known as “chronic Lyme disease”

Deaths and complications due to treating the fake disease known as “chronic Lyme disease” Deaths and complications due to treating the fake disease known as "chronic Lyme disease" | ScienceBlogs Advertisment Search Search Toggle navigation Main navigation Deaths and complications due to treating the fake disease known as "chronic Lyme disease" By on June 20, 2017. In pseudomedicine, fake diseases predominate. Basically, fake diseases are diseases that do not exist in conventional medicine (...) is that the adrenal glands have become "fatigued" and thereby unable to produce adequate quantities of hormones, primarily the glucocorticoid cortisol, due to chronic stress or infections. Of course, there is It is . That hasn't stopped a veritable industry devoted to selling "adrenal supplements" and other quackery to treat this nonexistent condition from cropping up. Chronic lyme disease is another prototypical . This should be contrasted to Lyme disease, which is a real diagnosis and a caused by the tick-borne

2017 Respectful Insolence

13. Serologic Evidence of Tick-Borne Encephalitis Virus Infection in a Patient with Suspected Lyme Disease in Japan. (PubMed)

Serologic Evidence of Tick-Borne Encephalitis Virus Infection in a Patient with Suspected Lyme Disease in Japan. Tick-borne encephalitis (TBE) is widely prevalent on the Eurasian continent, including Japan, but four cases of TBE have been reported in Japan. To inspect unconfirmed TBE cases in Japan, we conducted a retrospective seroepidemiological study of a total of 158 samples from 81 meningoencephalitis patients suspected as Lyme disease. Two serum samples from one patient showed (...) neutralizing antibodies against TBE virus. The patient with severe and progressive encephalitis had a history of tick bite in Hokkaido in 2012. These results demonstrated that tick-borne encephalitis virus (TBEV) case was actually unconfirmed in Japan. Further seroepidemiological surveys are required to identify unconfirmed TBEV infections to consider the pros and cons of introducing specific countermeasures including vaccination in Japan.

2018 American Journal of Tropical Medicine & Hygiene

14. Interventions to prevent Lyme disease in humans: A systematic review (Full text)

Interventions to prevent Lyme disease in humans: A systematic review Lyme disease (LD) is an infection transferred to humans through bites from infected ticks. Surveillance indicates that the number of LD cases is increasing in the UK, therefore, improved knowledge about reducing transmission from ticks to humans is needed. Eighteen electronic databases were searched and additional web-based searching was conducted, to locate empirical research, published from 2002 onwards. Sixteen studies (...) that evaluated five types of prevention intervention were included: personal protection (n = 4), domestic strategies (landscape modification and chemical pest control) (n = 3), education (n = 6), vaccination (n = 3), and deer-reduction programmes (n = 2). In general the quality of evidence was low. Results suggest that personal protection strategies, including the use of tick repellents and wearing of protective clothes, can prevent tick bites and reduce the incidence of LD among adults. Educational

2018 Preventive medicine reports PubMed

15. Borrelia burgdorferi Infection and Lyme Disease in North American Horses: A Consensus Statement (Full text)

Borrelia burgdorferi Infection and Lyme Disease in North American Horses: A Consensus Statement Borrelia burgdorferi infection is common in horses living in Lyme endemic areas and the geographic range for exposure is increasing. Morbidity after B. burgdorferi infection in horses is unknown. Documented, naturally occurring syndromes attributed to B. burgdorferi infection in horses include neuroborreliosis, uveitis, and cutaneous pseudolymphoma. Although other clinical signs such as lameness (...) and stiffness are reported in horses, these are often not well documented. Diagnosis of Lyme disease is based on exposure to B. burgdorferi, cytology or histopathology of infected fluid or tissue and antigen detection. Treatment of Lyme disease in horses is similar to treatment of humans or small animals but treatment success might not be the same because of species differences in antimicrobial bioavailability and duration of infection before initiation of treatment. There are no approved equine label Lyme

2018 Journal of Veterinary Internal Medicine PubMed

16. Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

) into the deltoid region on Days 0, 28 and 56. Study participants will be followed up until one year after first vaccination. Booster Extension: Subjects in the 48µg and 90µg Treatment groups who received a complete Primary immunization schedule will be included into a Booster Extension 13 months after the first immunization. Condition or disease Intervention/treatment Phase Lyme Borreliosis, Nervous System Biological: VLA15 with Alum Biological: VLA15 without Alum Phase 1 Detailed Description (...) Multivalent Recombinant OspA Vaccine Additional relevant MeSH terms: Layout table for MeSH terms Borrelia Infections Lyme Neuroborreliosis Gram-Negative Bacterial Infections Bacterial Infections Spirochaetales Infections Central Nervous System Bacterial Infections Lyme Disease Tick-Borne Diseases Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Vaccines Aluminum sulfate Aluminum Hydroxide Immunologic Factors Physiological Effects of Drugs Adjuvants, Immunologic

2016 Clinical Trials

17. Xylocaine and Lyme disease: A deer tick story

to finally remove the tick, I added: “We vaccinate dogs for Lyme disease here, but not people, but in Sweden, all my relatives have been vaccinated.” I grabbed the handles of the forceps, pointed the tip away from me, reached into the cymba conchae while still holding the boy’s head in place. Then I closed the tip of the forceps gently, without locking the instrument, and pulled. The tick offered no resistance. It was intact. “See, here he is, legs, jaw and all, out of where he doesn’t belong.” The boy (...) Xylocaine and Lyme disease: A deer tick story Xylocaine and Lyme disease: A deer tick story Xylocaine and Lyme disease: A deer tick story | | May 24, 2017 240 Shares It was a small deer tick, hidden by the crus helix, embedded in the cymba conchae, the crevice just above the ear canal of my seven-year-old patient halfway through my Saturday clinic. He was worried that it would hurt. His parents hadn’t wanted to try removing it on their own. I had a hard time even seeing the small tick

2017 KevinMD blog

18. Identification of Tp0751 (Pallilysin) as a Treponema pallidum Vascular Adhesin by Heterologous Expression in the Lyme disease Spirochete (Full text)

Identification of Tp0751 (Pallilysin) as a Treponema pallidum Vascular Adhesin by Heterologous Expression in the Lyme disease Spirochete Treponema pallidum subsp. pallidum, the causative agent of syphilis, is a highly invasive spirochete pathogen that uses the vasculature to disseminate throughout the body. Identification of bacterial factors promoting dissemination is crucial for syphilis vaccine development. An important step in dissemination is bacterial adhesion to blood vessel surfaces

2017 Scientific reports PubMed

19. Surprise! Relatively small decreases in vaccine uptake can lead to big increases in vaccine-preventable disease!

comments By kitty (not verified) on 30 Jul 2017 to post comments By dingo199 (not verified) on 30 Jul 2017 to post comments By Panacea (not verified) on 31 Jul 2017 ) - if you provide a link, people will notice if you lie about what the link says, so you're better off just lying, and refusing to provide a link. to post comments By Tempus (not verified) on 31 Jul 2017 @kitty A Lyme vaccine can't work. You can catch Lyme disease every summer your entire life, never acquiring immunity from it. If you want (...) Surprise! Relatively small decreases in vaccine uptake can lead to big increases in vaccine-preventable disease! Surprise! Relatively small decreases in vaccine uptake can lead to big increases in vaccine-preventable disease! | ScienceBlogs Advertisment Search Search Toggle navigation Main navigation Surprise! Relatively small decreases in vaccine uptake can lead to big increases in vaccine-preventable disease! By on July 26, 2017. One of the most common tropes used by antivaxers is to attack

2017 Respectful Insolence

20. Reservoir Targeted Vaccine Against Borrelia burgdorferi: A New Strategy to Prevent Lyme Disease Transmission. (Full text)

Reservoir Targeted Vaccine Against Borrelia burgdorferi: A New Strategy to Prevent Lyme Disease Transmission. A high prevalence of infection with Borrelia burgdorferi in ixodid ticks is correlated with a high incidence of Lyme disease. The transmission of B. burgdorferi to humans can be disrupted by targeting 2 key elements in its enzootic cycle: the reservoir host and the tick vector. In a prospective 5-year field trial, we show that oral vaccination of wild white-footed mice resulted in outer (...) surface protein A-specific seropositivity that led to reductions of 23% and 76% in the nymphal infection prevalence in a cumulative, time-dependent manner (2 and 5 years, respectively), whereas the proportion of infected ticks recovered from control plots varied randomly over time. Significant decreases in tick infection prevalence were observed within 3 years of vaccine deployment. Implementation of such a long-term public health measure could substantially reduce the risk of human exposure to Lyme

2014 Journal of Infectious Diseases PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>